The phase 2 trial reported that GI events were the most common adverse effects across all dose groups, and they were dose-dependent, meaning they increased in frequency and severity as the dose went up
CEO John Furner said during an earnings call in November that while it was still too early to tell how this will affect customers and the business, the company has seen "some shifts in categories." Before that, Furner acknowledged in an interview with Bloomberg that the company sees "a slight pullback in overall basket." "Just less units, slightly less calories," he said
Walczak-Jedrzejowska, R., Wolski, J
For Injection Training and Technical Support: Comprehensive injection training resources including video tutorials, written guides, and healthcare provider consultation are available through the ReadyRx patient portal following enrollment in injectable glutathione programs